Multiple antiviral and monoclonal antibody therapies are now available for mild-moderate COVID-19 in high-risk patients ≥12 years of age. However, data for the use of these agents in children is limited. We reviewed 94 pediatric patients for whom early therapy was requested since the emergence of the Omicron variant and describe patient characteristics, treatment logistics and associated short-term events.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9725736 | PMC |
| http://dx.doi.org/10.1097/INF.0000000000003740 | DOI Listing |
Publication Analysis
Top Keywords
monoclonal antibody
8
pediatric patients
8
antibody antiviral
4
antiviral therapy
4
therapy mild-to-moderate
4
mild-to-moderate covid-19
4
covid-19 pediatric
4
patients multiple
4
multiple antiviral
4
antiviral monoclonal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!